

REMARKS/ARGUMENTS

Claims 2, 16-18, 22, 24, 25, 32, 34, 35 and 63-114 are being cancelled. Claims 1, 19-21, 23, 26-28, 30, 31, 33, 36-38 and 42 are being amended. No new matter has been introduced by the amendments.

After entry of the above amendments, claims 1, 3-15, 19-21, 23, 26-31, 33 and 36-62 will be pending.

Election/Restriction


In the Office Action, the Examiner appears to maintain the restriction requirement originally presented in the Office Action dated April 27, 2006. While Applicants continue to believe that claim 1 is a linking claim and that the restriction requirement should be withdrawn, claims 1, 28, 30, 31, 33, 36-38 and 42 are being amended to delete reference to non-elected subject matter. In addition, claims 19-21 are being amended to be consistent with the cancellation of claim 17. Applicants note that the amendments are being presented solely for the purpose of advancing prosecution of the present application.

Information Disclosure Statements


Applicants note that two (2) supplemental Information Disclosure Statements ("IDSs") were filed on September 26, 2006 and November 15, 2006, in connection with the present application. Initialed copies of the Forms 1449 are requested.

Rejections under 35 USC §102


Claims 1-3, 11-12, 14, 24, 32, 33, 42, 43, 55, 56 and 58-60 are rejected as being anticipated by WO 01/23364 (Barnickel *et al.*). Barnickel *et al.* relates to glycoprotein IbIX antagonists having the general formula:



In particular, Barnickel *et al.* discloses 3-(3-aminomethyl-cyclohexylmethyl)-quinazolin-4-ones of the formula:



Applicants are amending the claims so that all of compounds are all of the formula:



wherein R_m is an aryl group. Since Barnickel *et al.* neither teaches nor suggests the presently claimed compounds, the rejection of claims 1-3, 11-12, 14, 24, 32, 33, 42, 43, 55, 56 and 58-60 under 35 USC §102 should be withdrawn.

Rejections under 35 USC §112, Second Paragraph

Claims 1-33, 36, 42, 43, 55-61, 87, 88, 95, 99, 100 and 103 are rejected as allegedly being indefinite.

With respect to the term “substituted,” Applicants maintain that one of ordinary skill in the art would understand the bounds of the term “substituted” as it is used in the present claims, and that the rejection is improper. However, for the sole purpose of advancing prosecution of the present application, Applicants are amending claims 1 and 42 to recite specific substituents for R_m. Support for the amendment can be found, for example, in the specification at paragraph [0200]. In addition, claim 1 is being amended to provide specific substituents for the ring formed by R₃ and R₄. Support for the amendment can be found, for example, in the specification at paragraph [0098], as well as in originally filed claim 42.

Similarly, with respect to the phrase “U is a moiety providing 1-6 atom separation,” Applicants also maintain that those skilled in the art would readily understand that U is a “linker” that joins V to the ring of the compound of Formula XIX. Again however, for the sole purpose

of advancing prosecution of the present application, Applicants are amending claims 1 and 42 to recite that U provides a 3 atom separation between V and the ring to which R₂ is attached.

The Examiner also indicates that use of the transitional phrase "comprising" in the claims is indefinite. Claims 1 and 42 are being amended to replace the phrase "[a] compound comprising Formula..." with the phrase "[a] compound of Formula...".

The claims are also rejected because the phrase "V comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein" is allegedly indefinite. Claims 1 and 42 are being amended to recite that V comprises a primary, secondary or tertiary amine, a heterocycloalkyl comprising a nitrogen ring atom, or a heteroaryl comprising a nitrogen ring atom wherein the amine, heterocycloalkyl or heteroaryl comprises a basic nitrogen atom that is capable of interacting with a carboxylic acid side chain of an active site residue of a protein. Support for the amendment can be found, for example, in original claims 2, 5 and 6.

In addition, with respect to the phrase "R₃ and R₄ are taken together to form... a 5 or 6 membered ring," Applicants maintain that one of ordinary skill in the art would understand the bounds of the phrase "R₃ and R₄ are taken together to form... a 5 or 6 membered ring" as it is used in the present claims. However, for the sole purpose of advancing prosecution of the present application, Applicants are amending claim 1 to recite that R₃ and R₄ are taken together to form a substituted 6 membered ring. Support for the amendment can be found, for example, in original claim 42.

Miscellaneous Amendments to the Claims

Claims 23 and 31 are being amended to clarify the meaning of substituent R₉. Support for the amendment can be found, for example, in original claim 1.

Claims 26-28, 30, and 31 are being amended to reflect the amendment of claim 1 with respect to R_m.

Claims 33 and 36-38 are being amended to reflect the amendment of claim 1 with respect to R₃ and R₄.

Double Patenting

The Examiner has provisionally rejected claims 1-33, 36, 42, 43, 55-61, 87, 88, 95, 99, 100 and 103 under the doctrine of non-statutory obviousness-type double patenting as being unpatentable over claims 1-5, 8, 9, 11-17, 19, 23, 26, 27, 29, 37-39, 51-57, 83, 84, 95, 99 and 111 of copending Application No. 10/809,635. Since the rejection is provisional, Applicants intend to address the rejection when one or both of the applications are otherwise in condition for allowance.

CONCLUSION

Applicants earnestly believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

Respectfully submitted,
Takeda San Diego, Inc.

Dated: January 3, 2007

By: David J. Weitz
David J. Weitz
Reg. No. 38,362

Customer No. 32793
Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121
Telephone: (858) 622-8528
Facsimile: (858) 550-0992